Horizon to Buy High-throughput Screening Business CombinatoRx for $8M | GenomeWeb

NEW YORK (GenomeWeb) – Horizon Discovery Group today announced an agreement to buy the CombinatoRx Service business of biopharmaceutical firm Zalicus for £4.74 million ($8.0 million).

CombinatoRx provides combination high-throughput screening (cHTS) services. Upon completion of the deal it will operate as a wholly owned subsidiary of Horizon and be called Horizon CombinatoRx. The new company will be located in a 23,000-square-foot facility in Cambridge, Mass.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.